LGD-4033

This page shows anti-doping rule violation data we have registered for LGD-4033.

Number of cases in LGD-4033 Last 10 Years

LGD-4033

LGD-4033 ranks #30 globally among prohibited substances, with 108 registered cases (0.7% of all violations) among all sports tracked by the Anti-Doping Database, which contains 14,670 verified cases. Australia leads with 17 cases, while Track and field is the most affected sport (21 cases).

Cases of LGD-4033 by Sport
Track and field
21
Weightlifting
14
Rugby
12
Bodybuilding
9
Cycling
9
Top Sport: Track and field

21

Track and field cases

0%

Of all violations

108

Total LGD-4033 cases
Track and field's share of LGD-4033 violations 0%
21 of 108

Track and field has the most recorded cases of LGD-4033 violations globally, with 21 registered cases — 0% of all 108 verified cases.

Cases of LGD-4033 by Country
Australia
17
Canada
13
USA
9
Russia
8
Belarus
7
Top Country: Australia

17

Australia cases

15.7%

Of all violations

108

Total LGD-4033 cases
Australia's share of LGD-4033 violations 15.7%
17 of 108

Australia leads in LGD-4033 violations globally, with 17 registered cases — 15.7% of all 108 verified cases.

Global Substance Ranking

LGD-4033 ranks #30 of 358 prohibited substances in the Anti-Doping Database.

#1 Stanozolol
1,359
#2 Methandienone
833
#3 Norandrosterone
778
#4 Testosterone
758
···
#30 LGD-4033
108
About This Ranking

This ranking covers only prohibited substances with verified case records in the Anti-Doping Database. Procedural violations (whereabouts failures, refusals to test, etc.) are excluded.

Active Sanctions — Expiry Year
Gender Distribution
Male 76.9%
83 cases
Female 23.1%
25 cases
Analysis: 's gender distribution (76.9% male, 23.1% female) aligns closely with the global average. Global average: 80.2% male, 19.8% female
Average Suspension Length
43.2
months
LGD-4033
30.1
months
Global average

The average suspension for LGD-4033 violations is 43.2 months, longer than the global average of 30.1 months.

LGD-4033 is an investigational selective androgen receptor modulator (SARM) for treatment of conditions such as muscle wasting and osteoporosis, discovered by Ligand Pharmaceuticals and currently under development by Viking Therapeutics. LGD-4033, originally developed for the treatment of muscle wasting conditions such as aging, osteoporosis, muscular dystrophy and cancer, is promoted as a selective non-steroidal anabolic agent. It is claimed to be a substance that induces muscle (and bone) growth without the side effects associated with steroid use. However, information on the safety of LGD-4033 is scarce due to a lack of medium and long-term clinical trials - hence the medium and long-term health impacts are unknown. It should be noted that a number of Selective Androgen Receptor Modulators (SARMs) have associated health-risks, particularly for the heart and liver. (Sources: Sports Integrity Australia, Wikipedia)

If you use this data, please credit The Anti-Doping Database

The intelligence tool for anti-doping professionals

Used by journalists, sport lawyers, NADOs and researchers worldwide for proactive strategy — not just post-case research.

 

As a subscriber you get instant access to verified, structured anti-doping case data — from hours of research to seconds:

  • Complete athlete and sanction details
    • Identity, ban periods, substances used, test type, violation information and more.
  • Verified documents and case materials
    • Access sanction decisions, PDFs and official sources when available.
  • Advanced insights and historical trends
    • Statistics across sports, countries, substances and year-by-year comparisons — for proactive planning, not just post-case analysis.

The Anti-Doping Database currently contains 14,670 verified anti-doping rule violations across all sports and all countries, and is updated regularly.